Price Target Review: Enterprise Products Partners L.P. (NYSE:EPD), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Enterprise Products Partners L.P. (NYSE:EPD) shares have a current ABR (average broker recommendation) of N/A. This recommendation is offered by Zacks Research. The rating lands on a sliding numerical scale from 1 to 5. A recommendation of 5 would indicate a Strong Sell, and a 1 would signify a Strong Buy. The mean rating may help provide a general sense of analyst sentiment on company shares.

Sell-side analysts taken into consideration by Zacks have also provided price target estimates on shares of Enterprise Products Partners L.P. (NYSE:EPD). The highest current target is $N/A. The lowest price target out of the polled analysts is presently $N/A. The consensus target price is currently noted at $N/A. Analysts may employ various techniques to help predict future stock price levels.

On the earnings front, Enterprise Products Partners L.P. (NYSE:EPD) is expected to post quarterly earnings per share of $N/A. This is the current consensus figure provided by Zacks. Investors and analysts will be looking for the company to next post earnings on or around N/A. Enterprise Products Partners L.P. (NYSE:EPD) most recently reported quarterly EPS of $N/A for the quarter ending N/A. The gap between the actual and the projected estimate leading up to earnings created a surprise factor of N/A%.

Wall Street sell-side research analysts covering Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares have recently provided various price target projections on where the stock might be going. According to them, the stock is expected to reach $N/A on a consensus level within the next year, according to Zacks. The most bullish estimate sees the stock reaching $N/A while the most conservative estimate stand at $N/A.

Zacks also gives an average broker rating based on the sell-side recommendations from the analysts who cover Alexion Pharmaceuticals, Inc.. They give the company shares an ABR of N/A. This is based on the N/A analysts taken into consideration by Zacks.

Earnings Estimates for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Currently, Wall Street is projecting that the firm will post $N/A earnings per share. This consensus number is also derived from Zacks. For the most recent period which ended on N/A, Alexion Pharmaceuticals, Inc.'s EPS was reported as $N/A. This created a “surprise factor” N/A% due to being $N/A apart from what Wall Street predicted. When actual numbers differ greatly from the consensus expectations, sharp movement in the stock price can often be seen in the hours or days following the report.

Investors will mark their calendars for N/A, the date when Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) are expected to release their quarterly results.

By Standard Staff Contributor